| Literature DB >> 26169272 |
Raul Herrera1, Charles Anderson1, Krishan Kumar1, Alvaro Molina-Cruz2, Vu Nguyen1, Martin Burkhardt1, Karine Reiter1, Richard Shimp1, Randall F Howard3, Prakash Srinivasan2, Michael J Nold4, Daniel Ragheb5, Lirong Shi5, Mark DeCotiis1, Joan Aebig1, Lynn Lambert1, Kelly M Rausch1, Olga Muratova1, Albert Jin6, Steven G Reed3, Photini Sinnis5, Carolina Barillas-Mury2, Patrick E Duffy1, Nicholas J MacDonald1, David L Narum7.
Abstract
The extended rod-like Plasmodium falciparum circumsporozoite protein (CSP) is comprised of three primary domains: a charged N terminus that binds heparan sulfate proteoglycans, a central NANP repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain. Only the last two domains are incorporated in RTS,S, the leading malaria vaccine in phase 3 trials that, to date, protects about 50% of vaccinated children against clinical disease. A seroepidemiological study indicated that the N-terminal domain might improve the efficacy of a new CSP vaccine. Using a panel of CSP-specific monoclonal antibodies, well-characterized recombinant CSPs, label-free quantitative proteomics, and in vitro inhibition of sporozoite invasion, we show that native CSP is N-terminally processed in the mosquito host and undergoes a reversible conformational change to mask some epitopes in the N- and C-terminal domains until the sporozoite interacts with the liver hepatocyte. Our findings show the importance of understanding processing and the biophysical change in conformation, possibly due to a mechanical or molecular signal, and may aid in the development of a new CSP vaccine.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26169272 PMCID: PMC4567636 DOI: 10.1128/IAI.02676-14
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441